Sofosbuvir, Velpatasvir and Voxilaprevir for Treatment of Chronic Hepatitis C Virus Patients Non-Responder to Previous Sofosbuvir-Daclatasvir Therapy

Abstract Background Egypt is one of the countries with a high HCV burden; the percentage of HCV antibody positivity is 4.61 % of Egyptian general population. The advent of oral direct-acting antivirals (DAAs), as a treatment for chronic hepatitis C (CHC), has revolutionized the field with obvious safety and efficacy privileges. Despite the high rates of SVR achieved with DAAs, HCV is not eliminated from a considerable proportion of patients (1-15%). So, a new problem has emerged which is the need for re-treatment of patients who couldn’t be cured with DAAs in the first instance. Aim of the Work to evaluate the efficacy of sofosbuvir, velpatasvir, voxilaprevir for previously DAA-(Sofosbuvir–Daclatasvir)-treated Egyptian patients who failed to achieve SVR after their treatment. Patients and Methods This study was performed in Ahmed Maher Teaching Hospital, Cairo, Egypt, Internal Medicine Department. The study included 139 patients with chronic hepatitis C Non- responder to Previous Sofosbuvir-Daclatasvir Therapy. Patients enrolled in the study were prospectively evaluated as outpatients by the study staff at 4, 8, 12 weeks and at 12 weeks post-treatment. All the patients were subjected to history taking, clinical examination, complete biochemical and virological studies. Results The overall treatment outcome: there was a statistically highly significant difference in PCR before treatment (100%+ve) and after treatment (97.1%-ve) 3 month after treatment. Throughout the study, most of the patients were responders (97.1% achieved SVR 12). Conclusion Rescue therapy with SOF/VEL/VOX is safe and highly effective, for treatment of chronic hepatitis C virus patients non-responder to previous Sofosbuvir-Daclatasvir therapy achieving SVR12 rates 97.1%.